GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Cash Flow from Investing

Shanghai Junshi Biosciences Co (HKSE:01877) Cash Flow from Investing : HK$-245.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Shanghai Junshi Biosciences Co spent HK$230.6 Mil on purchasing property, plant, equipment. It gained HK$0.0 Mil from selling property, plant, and equipment. It spent HK$0.0 Mil on purchasing business. It gained HK$0.0 Mil from selling business. It spent HK$27.2 Mil on purchasing investments. It gained HK$162.9 Mil from selling investments. It paid HK$0.0Mil for net Intangibles purchase and sale. And it received HK$15.3 Mil from other investing activities. In all, Shanghai Junshi Biosciences Co spent HK$79.6 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Shanghai Junshi Biosciences Co Cash Flow from Investing Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Cash Flow from Investing Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -1,059.37 -827.40 -2,303.16 -522.20 -976.11

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -561.38 363.85 -529.51 - -79.59

Shanghai Junshi Biosciences Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Shanghai Junshi Biosciences Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Shanghai Junshi Biosciences Co's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-245.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Shanghai Junshi Biosciences Co's purchase of property, plant, equipment for the three months ended in Mar. 2024 was HK$-230.6 Mil. It means Shanghai Junshi Biosciences Co spent HK$230.6 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Shanghai Junshi Biosciences Co's sale of property, plant, equipment for the three months ended in Mar. 2024 was HK$0.0 Mil. It means Shanghai Junshi Biosciences Co gained HK$0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Shanghai Junshi Biosciences Co's purchase of business for the three months ended in Mar. 2024 was HK$0.0 Mil. It means Shanghai Junshi Biosciences Co spent HK$0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Shanghai Junshi Biosciences Co's sale of business for the three months ended in Mar. 2024 was HK$0.0 Mil. It means Shanghai Junshi Biosciences Co gained HK$0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Shanghai Junshi Biosciences Co's purchase of investment for the three months ended in Mar. 2024 was HK$-27.2 Mil. It means Shanghai Junshi Biosciences Co spent {stock_data.stock.currency_symbol}}27.2 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Shanghai Junshi Biosciences Co's sale of investment for the three months ended in Mar. 2024 was HK$162.9 Mil. It means Shanghai Junshi Biosciences Co gained HK$162.9 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Shanghai Junshi Biosciences Co's net Intangibles purchase and sale for the three months ended in Mar. 2024 was HK$0.0 Mil. It means Shanghai Junshi Biosciences Co paid HK$0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Shanghai Junshi Biosciences Co's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.0 Mil. It means Shanghai Junshi Biosciences Co paid HK$0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Shanghai Junshi Biosciences Co's cash from other investing activities for the three months ended in Mar. 2024 was HK$15.3 Mil. It means Shanghai Junshi Biosciences Co received HK$15.3 Mil from other investing activities.


Shanghai Junshi Biosciences Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
Executives
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd 2101 Beneficial owner
Jovial Champion Investments Limited 2201 Interest of corporation controlled by you
Gong Ruilin 2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited 2201 Interest of corporation controlled by you
Lvc Holdings Limited 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lvc Innovate Limited 2201 Interest of corporation controlled by you
Lin Lijun 2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp 2101 Beneficial owner
Lvc Renaissance Limited 2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited 2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines